Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Avalo Therapeutics, Inc. (AVTX) had Normalized Pre-Tax Income of $-19.62M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-19.63M |
|
-- |
|
-- |
|
$20.90M |
|
$-20.90M |
|
$1.28M |
|
$-19.62M |
|
|
Normalized Pre-Tax Income |
$-19.62M |
$-19.63M |
|
$-19.63M |
|
$-19.63M |
|
$-19.63M |
|
$-20.90M |
|
$-20.88M |
|
20.11M |
|
20.11M |
|
$-0.98 |
|
$-0.98 |
|
| Balance Sheet Financials | |
$88.83M |
|
$0.38M |
|
$11.06M |
|
$99.89M |
|
$11.60M |
|
-- |
|
$19.97M |
|
$31.57M |
|
$68.32M |
|
$57.82M |
|
$68.32M |
|
24.64M |
|
| Cash Flow Statement Financials | |
$-17.69M |
|
$25.50M |
|
$1.40M |
|
$16.11M |
|
$25.32M |
|
$9.21M |
|
$3.58M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.66 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-17.69M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-28.73% |
|
-33.95% |
|
-19.65% |
|
-28.73% |
|
$2.77 |
|
$-0.88 |
|
$-0.88 |
|